Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Chief Commercial Officer | January 31, 2020 | February 04, 2020 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | EVP, Head of North America | August 13, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date January 31, 2020 · Filed February 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.26 · Expires 2030-01-30 | Direct | 125,000 |
Reported balance
After 2020-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-31 · Grant · Acquired 125,000 · Balance 125,000 F1: The options vest ratably over a four-year period beginning on January 20, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest ratably over a four-year period beginning on January 20, 2020.
RHYTHM PHARMACEUTICALS, INC.
Report date August 13, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-13 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-13 · Exercise / conversion · Acquired 35,000 · Balance 54,233 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. Row 2 · 2026-08-13 · Exercise / conversion · Acquired 21,601 · Balance 75,834 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. Row 3 · 2026-08-13 · Sale · Disposed 75,834 · Balance 0 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.29 · Expires 2030-11-09 | Direct | 36,283 |
Reported balance
After 2026-08-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-13 · Exercise / conversion · Disposed 35,000 · Balance 36,283 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F2: The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2032-02-08 | Direct | 0 |
Reported balance
After 2026-08-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-13 · Exercise / conversion · Disposed 21,601 · Balance 0 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F3: The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.
F2: The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
F3: The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2024 Filed Mar 20, 2024 00:52 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 15,515 | $39.22 | $608,498.30 |
DisclosureSEC source: 0001104659-24-036312 · tm249308-2_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,087 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.07 to $39.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $49.23 | $0.00 |
DisclosureSEC source: 0001104659-24-026154 · tm246920-1_4seq1.xml · derivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2034-02-15 F4 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026154 · tm246920-1_4seq1.xml · derivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantCommon Stock | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026154 · tm246920-1_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,602 F1 · shares: The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 01:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 615 | $49.83 | $30,645.45 |
DisclosureSEC source: 0001104659-24-022538 · tm246165-3_4seq1.xml · nonDerivative · entry 4 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,852 F2 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 01:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,023 | $51.38 | $52,561.74 |
DisclosureSEC source: 0001104659-24-022538 · tm246165-3_4seq1.xml · nonDerivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,467 F2 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2024 Filed Feb 14, 2024 01:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022538 · tm246165-3_4seq1.xml · derivative · entry 6 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,031 Underlying: Common Stock · 2,031 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2024 Filed Feb 14, 2024 01:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,031 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-022538 · tm246165-3_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022538 · tm246165-3_4seq1.xml · derivative · entry 5 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,874 Underlying: Common Stock · 3,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-022538 · tm246165-3_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:55 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010800 · tm245251-5_4seq1.xml · derivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,537 Underlying: Common Stock · 4,513 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:55 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,492 | $45.06 | $67,229.52 |
DisclosureSEC source: 0001104659-24-010800 · tm245251-5_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,021 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:55 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,513 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-010800 · tm245251-5_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,030 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-23-119095 · tm2330902-2_4seq1.xml · derivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,412 Underlying: Common Stock · 12,030 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 13,677 | $32.01 | $437,818.55 |
DisclosureSEC source: 0001104659-23-119095 · tm2330902-2_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $32.00 to $32.125. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 12,030 | $6.80 | $81,804.00 |
DisclosureSEC source: 0001104659-23-119095 · tm2330902-2_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 22:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,438 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-23-117365 · tm2330582-1_4seq1.xml · derivative · entry 8 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,442 Underlying: Common Stock · 3,438 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 22:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,719 | $28.00 | $48,132.00 |
DisclosureSEC source: 0001104659-23-117365 · tm2330582-1_4seq1.xml · nonDerivative · entry 6 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,647 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 22:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,719 | $27.37 | $47,051.09 |
DisclosureSEC source: 0001104659-23-117365 · tm2330582-1_4seq1.xml · nonDerivative · entry 5 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,366 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $26.86 to $27.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 22:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,438 | $6.80 | $23,378.40 |
DisclosureSEC source: 0001104659-23-117365 · tm2330582-1_4seq1.xml · nonDerivative · entry 4 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 22:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,712 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-23-117365 · tm2330582-1_4seq1.xml · derivative · entry 7 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,880 Underlying: Common Stock · 5,712 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 22:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,233 | $29.31 | $65,455.71 |
DisclosureSEC source: 0001104659-23-117365 · tm2330582-1_4seq1.xml · nonDerivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,647 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.04 to $29.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 22:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,479 | $28.64 | $99,648.65 |
DisclosureSEC source: 0001104659-23-117365 · tm2330582-1_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,880 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $28.04 to $29.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 22:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,712 | $6.80 | $38,841.60 |
DisclosureSEC source: 0001104659-23-117365 · tm2330582-1_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 23:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 80 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-23-115368 · tm2330154-1_4seq1.xml · derivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,592 Underlying: Common Stock · 80 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 23:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 80 | $28.00 | $2,240.00 |
DisclosureSEC source: 0001104659-23-115368 · tm2330154-1_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,647 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 23:17 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 80 | $6.80 | $544.00 |
DisclosureSEC source: 0001104659-23-115368 · tm2330154-1_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 21:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,519 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-23-099017 · tm2325695-1_4seq1.xml · derivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,672 Underlying: Common Stock · 4,519 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 21:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 6,166 | $28.05 | $172,957.53 |
DisclosureSEC source: 0001104659-23-099017 · tm2325695-1_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,647 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $28.00 to $28.25. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 21:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,519 | $6.80 | $30,729.20 |
DisclosureSEC source: 0001104659-23-099017 · tm2325695-1_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,718 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-23-089331 · tm2323302-1_4seq1.xml · derivative · entry 6 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,191 Underlying: Common Stock · 1,718 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,718 | $24.66 | $42,365.88 |
DisclosureSEC source: 0001104659-23-089331 · tm2323302-1_4seq1.xml · nonDerivative · entry 4 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,294 F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,718 | $6.80 | $11,682.40 |
DisclosureSEC source: 0001104659-23-089331 · tm2323302-1_4seq1.xml · nonDerivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,591 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-23-089331 · tm2323302-1_4seq1.xml · derivative · entry 5 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,909 Underlying: Common Stock · 8,591 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 11,223 | $24.18 | $271,347.45 |
DisclosureSEC source: 0001104659-23-089331 · tm2323302-1_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,294 F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 8,591 | $6.80 | $58,418.80 |
DisclosureSEC source: 0001104659-23-089331 · tm2323302-1_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 986 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2023. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 01:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 635 | $26.87 | $17,062.45 |
DisclosureSEC source: 0001104659-23-022113 · tm236871-9_4seq1.xml · nonDerivative · entry 2 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,940 F2 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 15, 2023 01:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-022113 · tm236871-9_4seq1.xml · derivative · entry 3 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,062 Underlying: Common Stock · 2,031 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2023 Filed Feb 15, 2023 01:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,031 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-022113 · tm236871-9_4seq1.xml · nonDerivative · entry 1 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-019835 · tm236605-6_4seq1.xml · derivative · entry 3 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,312 Underlying: Common Stock · 3,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,192 | $27.66 | $32,970.72 |
DisclosureSEC source: 0001104659-23-019835 · tm236605-6_4seq1.xml · nonDerivative · entry 2 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,556 F2 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-019835 · tm236605-6_4seq1.xml · nonDerivative · entry 1 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2023 Filed Feb 15, 2023 00:19 UTC Amendment | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,204 | $27.51 | $33,122.04 |
DisclosureSEC source: 0001104659-23-022065 · tm236871-2_4aseq1.xml · nonDerivative · entry 1 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,544 F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:06 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 46,900 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-23-010483 · tm235340-1_4seq1.xml · derivative · entry 2 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,900 Underlying: Common Stock · 46,900 shares Expires 2033-01-31 F3 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:06 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 18,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010483 · tm235340-1_4seq1.xml · derivative · entry 1 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,050 Underlying: Common Stock · 18,050 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 00:28 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 722 | $6.10 | $4,404.20 |
DisclosureSEC source: 0001104659-22-023948 · tm226880-1_4seq1.xml · nonDerivative · entry 2 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,310 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:28 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023948 · tm226880-1_4seq1.xml · derivative · entry 3 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,093 Underlying: Common Stock · 2,032 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:28 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,032 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-023948 · tm226880-1_4seq1.xml · nonDerivative · entry 1 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2022 Filed Feb 12, 2022 02:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-22-020887 · tm226394-1_4seq1.xml · derivative · entry 2 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2032-02-08 F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 09, 2022 Filed Feb 12, 2022 02:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-020887 · tm226394-1_4seq1.xml · derivative · entry 1 Chien Jennifer · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.